Oroxindin inhibits macrophage NLRP3 inflammasome activation in DSS-induced ulcerative colitis in mice via suppressing TXNIP-dependent NF-&#954;B pathway.

Liu, Qi; Zuo, Rui; Wang, Kai; Nong, Fei-Fei; Fu, Ya-Jun; Huang, Shao-Wei; Pan, Zeng-Feng; Zhang, Yi; Luo, Xia; Deng, Xiang-Liang; Zhang, Xiao-Xue; Zhou, Lian; Chen, Yang

Oroxindin inhibits macrophage NLRP3 inflammasome activation in DSS-induced ulcerative colitis in mice via suppressing TXNIP-dependent NF-κB pathway.

Liu, Qi; Zuo, Rui; Wang, Kai; Nong, Fei-Fei; Fu, Ya-Jun; Huang, Shao-Wei; Pan, Zeng-Feng; Zhang, Yi; Luo, Xia; Deng, Xiang-Liang; Zhang, Xiao-Xue; Zhou, Lian; Chen, Yang.

Afiliación

Liu Q; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Zuo R; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Wang K; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Nong FF; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Fu YJ; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Huang SW; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Pan ZF; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Zhang Y; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Luo X; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Deng XL; School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Zhang XX; Department of Laboratory Medicine, Affiliated Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Zhou L; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. zl@gzucm.edu.cn.
Chen Y; School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. ychen8@gzucm.edu.cn.

Acta Pharmacol Sin ; 41(6): 771-781, 2020 Jun.

Article en En | MEDLINE | ID: mdl-31937929

Asunto(s)

Proteínas Portadoras/antagonistas & inhibidores; Cromonas/farmacología; Colitis Ulcerosa/tratamiento farmacológico; Glucuronatos/farmacología; Inflamasomas/efectos de los fármacos; FN-kappa B/antagonistas & inhibidores; Proteína con Dominio Pirina 3 de la Familia NLR/antagonistas & inhibidores; Tiorredoxinas/antagonistas & inhibidores; Administración Oral; Animales; Proteínas Portadoras/metabolismo; Cromonas/administración & dosificación; Colitis Ulcerosa/inducido químicamente; Colitis Ulcerosa/patología; Sulfato de Dextran/administración & dosificación; Relación Dosis-Respuesta a Droga; Glucuronatos/administración & dosificación; Inflamasomas/metabolismo; Macrófagos/efectos de los fármacos; Macrófagos/metabolismo; Masculino; Ratones; Ratones Endogámicos C57BL; FN-kappa B/metabolismo; Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo; Relación Estructura-Actividad; Tiorredoxinas/metabolismo

Palabras clave

NF-κB signaling; NLRP3 inflammasome; TXNIP; anti-inflammatory; oroxindin; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tiorredoxinas / Proteínas Portadoras / Colitis Ulcerosa / FN-kappa B / Cromonas / Inflamasomas / Proteína con Dominio Pirina 3 de la Familia NLR / Glucuronatos Tipo de estudio: Prognostic_studies Idioma: En Revista: Acta Pharmacol Sin Asunto de la revista: FARMACOLOGIA Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google